Atara Biotherapeutics, Inc.
ATRA
$9.81
$1.0311.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 32.69M | 23.40M | 5.80M | -15.64M | -85.40M |
| Total Depreciation and Amortization | 2.12M | 2.17M | 4.36M | 5.46M | 5.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.99M | 29.88M | 36.66M | 44.28M | 42.59M |
| Change in Net Operating Assets | -104.74M | -125.17M | -110.73M | -101.34M | -30.96M |
| Cash from Operations | -50.94M | -69.71M | -63.92M | -67.24M | -68.72M |
| Capital Expenditure | -- | -90.00K | -90.00K | -119.00K | -246.00K |
| Sale of Property, Plant, and Equipment | 948.00K | 393.00K | 349.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.20M | 12.78M | -1.42M | 11.23M | 8.87M |
| Cash from Investing | 18.15M | 13.08M | -1.16M | 11.11M | 8.62M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -250.00K | -485.00K | -682.00K | -915.00K | -892.00K |
| Issuance of Common Stock | 16.35M | 52.23M | 50.72M | 50.81M | 60.19M |
| Repurchase of Common Stock | -- | -- | -- | -- | -6.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.00K | -35.97M | 480.00K | -15.01M | -7.00K |
| Cash from Financing | 16.10M | 15.77M | 50.52M | 34.89M | 59.28M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.69M | -40.86M | -14.56M | -21.25M | -811.00K |